Nouri Review
GLP-1 weight-loss telehealth · Independently scored 4.3/10
Best for: coaching bundled into the price rather than sold separately
Nouri falls below our bar on medical oversight. Read the breakdown below before you give it money.
Covered by the plan
Medication
Not stated
Clinician visits
Not stated
Shipping
In the price
Lab work
Not stated
Coaching
In the price
No insurance needed · Vetted by our editors
Flat per-dose pricing opens at $158/month where the drug is semaglutide, $250/month where it is tirzepatide, shipping included, in all 50 states. Planning for nutrition and movement, plus messaging with clinicians, is part of what is bought rather than an upsell. Nouri names Wasef Health, PC as its clinical partner and Jungle Jim's as its 503A pharmacy, and holds LegitScript certification.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Vetted alternatives to Nouri
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Nouri at a glance
- Type
- GLP-1 telehealth provider
- Medications
- Semaglutide, Tirzepatide
- Pricing model
- Flat — dose increases don't raise the monthly price
- What's included
- Shipping · Coaching
- Availability
- All 50 states
- FDA status
- 4 FDA warning letters on record — see below
How Nouri scores
Six columns, each one computed from something Nouri has published rather than from an opinion we formed: what it charges, which molecules it will dispense, what its record shows, and what the monthly figure actually buys. Where it publishes nothing, that absence is what gets scored. Every seller in the register goes through the same six columns.
Value25%
3.0/10No monthly price is published at all, so value cannot be measured against the register. Capped rather than scored.
Effectiveness25%
5.0/10Publishes no medication list or price, so what is prescribed here cannot be established. Held at the midpoint — this is a gap in the record, not a finding about the drugs.
User Experience15%
3.0/10On the seller's own pages, no price appears until the medical intake is finished.
Trust & Safety15%
2.0/104 FDA warning letters on record; does not name a dispensing pharmacy; withholds price until after the intake; publishes its state list. Our verification confidence is medium.
Accessibility10%
10.0/10Publishes coverage in 50 of 50 states.
Support10%
5.0/10No published price, so what a price would include cannot be assessed. Held at the midpoint.
A seller that will not show a price before an intake loses points on Value and carries that note in its review. Withholding the number is itself a finding. How we score →
What we checked on Nouri
Last checked July 2026- Checked state coverage: all 50
- Established what the monthly figure covers, and what it leaves out
- Searched our FDA enforcement register for this operator
Price, availability, and compliance here are read off the seller's own pages and off primary regulatory records, named in the sources below. Editorial confidence in this data: medium.
What signing up with Nouri involves
Assembled from this seller’s entry in the register — the price record, the state list, the dispensing pharmacy where one is named, and what the monthly figure covers. It describes what a reader can expect to meet on the way to a prescription, and what is missing from the seller’s own disclosures. It is not a clinical judgment and not a prescribing decision.
- 1Nouri does not show a price until you have worked through its medical questionnaire. Budget for the fact that you cannot compare it against anything until you have handed over health information.
- 2The intake is a written questionnaire. No live video visit or baseline bloodwork is recorded as required.
- 3Nouri does not say which pharmacy dispenses the medication. That is common here and it means you cannot check the pharmacy's record before you buy.
- 4The monthly price is recorded as covering shipping, coaching.
- No comparable monthly cash price for the medication is on record — either nothing is published, or what is published is a fee, an insured copay or a per-vial rate rather than a monthly cost.
- Coverage is published for all 50 states.
- 4 FDA warning letters on record. The letter itself is linked in the enforcement section below — read what it alleges rather than the fact that it exists.
Nouri support, as documented
- Phone
- (201) 972-5630
- help@joinnouri.com
GLP-1 medications Nouri offers
Each one has its own guide: how the molecule works, the dosing schedule, the side effects that show up in practice, and what the trials actually measured.
In its favor
- The monthly price is recorded as flat across doses, so it does not climb as the dose is titrated up
- The monthly figure covers shipping and coaching
- Coverage is published for all 50 states
Against it
- No price appears until the medical intake is complete, so the cost cannot be compared before health information is submitted
- No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
- 4 FDA warning letters matched to this operator in our enforcement register — read what the letter alleges, since a letter discloses a problem rather than disqualifying a seller
What Nouri charges
Nouri does not publish a standing monthly price. That is a choice, and it means you cannot compare it against anything until you have gone through an intake and been quoted. When you get that quote, ask specifically for the ongoing monthly figure and what it includes — not the first-month rate, and not a program total divided by its length.
What Nouri dispenses
Nouri prescribes semaglutide (approved as Wegovy and Ozempic) and tirzepatide (approved as Zepbound and Mounjaro). Between them these are the two molecules with the largest published weight-loss trial programs behind them.
What we could verify
On the record: it treats patients in all 50 states, clinician messaging is available between visits, it dispenses through an accredited compounding pharmacy, and coaching is included rather than sold on top. FDA has sent this operator a warning letter, and we flag it at the top of the page. A letter is a disclosure, not a disqualification: read what it actually says before deciding what it means for you. How we weigh oversight, disclosure and price evidence is set out in our scoring methodology.
Who should look elsewhere
- You want the FDA-approved pen specifically. Nothing here is the approved finished product.
- You need to compare prices before committing time to an intake — there is no published figure to compare.
- You need to bill insurance. Like most of this market, this is cash-pay.
- A regulatory record matters to you more than price does — read the warning letter flagged above before deciding.
It fits if
- you want the price to stop moving as your dose climbs
- you want coaching bundled rather than metered
- you need access regardless of where you live
- reaching a clinician between visits matters to you
Our read
We cannot tell you whether Nouri is priced well, because it does not say. That is not automatically disqualifying — plenty of legitimate operators quote after intake — but it does mean the comparison has to happen after you have spent the time, which is the wrong order for the buyer. CoreAge Rx is the nearest comparison we track, and worth reading alongside this. Whatever you decide, read the warning letter flagged at the top of this page first, and raise it with the clinician you would be prescribing through.
The Bottom Line
Nouri falls below our bar on medical oversight. Read the breakdown below before you give it money.
Before you pay Nouri
Check today's price, then book the free consultation.
Frequently Asked Questions
Glossary
The words sellers use, defined. Tap any term.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Sources
Cited across this Nouri review: primary regulatory filings, and peer-reviewed studies.
Sources & methodology — as of August 2026
- 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
See Nouri's current pricing
The free consultation is where you learn whether you qualify, and what it costs today.